2024 Review of All T1D Research Projects in Human Trials

July 23, 2024

This is the 12th annual analysis and review of active T1D human trials registered with the US FDA. Each clinical trial is combed through and categorized to determine trends, priorities, and how many trials are focused on achieving a Practical/Functional Cure. Categories are defined in Appendix C.

This report provides an essential viewpoint on the most developed T1D research—those in human trials. These trials indicate which research areas are prioritized and how the trajectory of their growth or decline changes as the years progress. Above all, these trials demonstrate the importance that must be placed on increased cure research, as the projects in human trials today are the only ones with a chance of developing into a Practical Cure within the next fifteen years.

Of the 634 active T1D trials today, only 11 trials—2%—aim to achieve a Practical Cure. Every Practical Cure trial is valued, but 2% is not enough. JDCA will release a comprehensive overview of all Practical Cure projects in human trials in the upcoming weeks.

All clinical trial data are from the FDA’s clinical trial database, downloaded and reviewed in June of this year. Any trials added to the database since then will be categorized in next year’s annual overview and updated on the JDCA website in real time.

By the Numbers

• 634 total active T1D trials (1% increase from 627 last year).
• 11 Practical Cure trials (2% of all trials; two less than last year).
• 91% increase in the number of T1D clinical trials since 2012 (see Appendix A).
• 25% address disease management, the largest category since 2020 (see Appendix B).
• 19% of trials address complications, an 8% increase from 2023.
• 43 trials address mental health, a 258% increase from 2020 and +26% from 2023.

Appendix A: Total T1D Trials vs. Practical Cure Trials (Historical)

Appendix B: 5-Year Trends in T1D Clinical Trials by Category

Appendix C: JDCA Research Category Definitions